Describing what they are about as re-inventing "Subcellular Research", the principals of the firm Panluminate are described as opening new frontiers for scientists; leading the evolution of biological imaging towards a three-dimensional, multi-modal, multi-resolution, and multiplexed era. The firm's proprietary next-generation pan-ExSt technology, is designed to empower investigators in academia and industry to explore uncharted territories in biomarker imaging, unlocking transformative insights that have been beyond reach until now. The firm's offered services for a wide range of investigations, including: Pre-clinical drug development in oncology; myloid plaque characterization in Alzheimers disease; Abnormalities in mitochondrial structures Deciphering Acute Kidney Injury (AKI) progression mechanisms and Mapping neural circuits in the mouse brain.Subcellular phenotypic profiling of human lung and breast cancer tissue
